34
Participants
Start Date
August 15, 2022
Primary Completion Date
September 30, 2027
Study Completion Date
March 31, 2029
ONO-4059
Tirabrutinib is a Bruton's Tyrosine Kinase Inhibitor. Tirabrutinib will be administered orally at a dose of 80 mg once daily after a meal (breakfast, lunch, or dinner).
ONO-4059 placebo
Placebo will be administered orally once daily after a meal (breakfast, lunch, or dinner).
RECRUITING
Ichinomiya Municipal Hospital, Aichi
RECRUITING
Nagoya City University Hospital, Aichi
RECRUITING
Kurume University Hospital, Fukuoka
RECRUITING
Fukushima Medical University Hospital, Fukushima
RECRUITING
Hokkaido University Hospital, Hokkaido
RECRUITING
Kagoshima University Hospital, Kagoshima
RECRUITING
St.Marianna University School of Medicine Hospital, Kanagawa
RECRUITING
Tokai University Hospital, Kanagawa
RECRUITING
Yokohama City University Hospital, Kanagawa
RECRUITING
University Hospital Kyoto Prefectural University of Medicine, Kyoto
RECRUITING
Niigata University Medical & Dental Hospital, Niigata
RECRUITING
Kawasaki Medical School Hospital, Okayama
RECRUITING
Kindai university hospital, Osaka
RECRUITING
Osaka Metropolitan University Hospital, Osaka
RECRUITING
Saitama Medical Center, Saitama
RECRUITING
Jichi Medical University Hospital, Tochigi
RECRUITING
Keio University Hospital, Tokyo
RECRUITING
Tokyo Medical and Dental University Hospital, Tokyo
RECRUITING
Tokyo Women'ｓ Medical University Hospital, Tokyo
NOT_YET_RECRUITING
Yamagata University Hospital, Yamagata
Lead Sponsor
Ono Pharmaceutical Co. Ltd
INDUSTRY